IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology
NEW YORK AND CAMBRIDGE, MASS. – JANUARY 27, 2022 – IAVI and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C.
https://www.iavi.org/news-resources/press-releases/2022/iavi-and-moderna-launch-trial-of-mrna-hiv-vaccine-antigens
Press Releases
January 27, 2022
IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology
NEW YORK AND CAMBRIDGE, MASS. – JANUARY 27, 2022 – IAVI and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C.